Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
|
|
|
- Neal Townsend
- 5 years ago
- Views:
Transcription
1 Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid
2 Stage III: heterogenous disease * Stage IIIA - IIIB * Performance Status * Number nodes stations * Resectable/UnResectable
3 Stage III: heterogenous disease T and M Descriptors N0 N1 N2 N3 6th Edition TNM 7th Edition TNM Stage Stage Stage Stage T1 (! 3 cm) T1a (! 2 cm) IA IIA IIIA IIIB T1b (> 2-3 cm) IA IIA IIIA IIIB T2a (> 3-5 cm) IB IIA (IIB) IIIA IIIB T2 (> 3 cm) T2b (> 5-7 cm) IIA (IB) IIB IIIA IIIB T3 (> 7 cm) IIB (IB) IIIA (IIB) IIIA IIIB T3 invasion T3 IIB IIIA IIIA IIIB T4 (same lobe nodules) T3 IIB (IIIB) IIIA (IIIB) IIIA (IIIB) IIIB T4 (extension) T4 IIIA (IIIB) IIIA (IIIB) IIIB IIIB M1 (ipsilateral lung) T4 IIIA (IV) IIIA (IV) IIIB (IV) IIIB (IV) T4 (pleural effusion) M1a IV (IIIB) IV (IIIB) IV (IIIB) IV (IIIB) M1 (contralateral lung) M1a IV IV IV IV M1 (distant) M1b IV IV IV IV Goldstraw JTO IASLC staging book 2009
4 Stage III: heterogenous disease * Stage IIIA - IIIB * Performance Status: weight loss / physiologic age / cardiopulmonary fitness * Number nodes stations: volume of disease / volume to XRT * Resectable/UnResectable
5 Stage III: heterogenous disease * Stage IIIA - IIIB * Performance Status * Number nodes stations * Resectable/UnResectable
6 N2: Resectable / UnResectable Definition Resectable / UnResectable / Bulky Disease Thoracic Surgeon Criteria UnResectable / Bulky Disease Different Definitions: - Nodes > 2 cm, extra nodal affections, several nodes stations - SWOG: Node > 3 cm - EORTC: any N2 with non squamous; affections 4R or 5L/6L
7 N2: Resectable / UnResectable
8 N2: Resectable / UnResectable Definition Resectable / UnResectable / Bulky Disease Thoracic Surgeon Criteria UnResectable / Bulky Disease Different Definitions: - Nodes > 2 cm, extra nodal affections, several nodes stations - SWOG: Node > 3 cm - EORTC: any N2 with non squamous; affections 4R or 5L/6L
9 EIIIA N2 Resectable
10 EIIIA N2 Resectable Intergroup 0139 Albain Lancet 2009
11 EIIIA N2 Resectable Intergroup 0139 Albain Lancet 2009
12 EIIIA N2 Resectable Intergroup 0139 OS Lobectomy vs CT/RT Albain Lancet 2009
13 EIIIA N2 UnResectable EORTC von Meerbeeck JNCI 2007
14 EIIIA N2 UnResectable EORTC von Meerbeeck JNCI 2007
15 EIIIA N2 Surgery for NSCLC T1-3N2M0 having pathologically verified N2: A prospective multinational phase III trial by the Nordic Thoracic Oncology Group Sorensen JCO 2013
16 EIIIA N2 Surgery for NSCLC T1-3N2M0 having pathologically verified N2: A prospective multinational phase III trial by the Nordic Thoracic Oncology Group Sorensen JCO 2013
17 EIIIA N2 Neo-adjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 nonsmall cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00)
18 This is the first completed phase III trial to investigate the value of the addition of neoadjuvant radiotherapy to CT and surgery. RT did not improve EFS or survival, nor did it reduce the local failure rate. Nevertheless, the overall survival rates of our neoadjuvant chemotherapy strategy confirm our previous report, and are among the best results reported to date in a multicenter setting.
19 E IIIA UnResectable / E IIIB
20 NSCLC Collaborative Group Meta Analysis Sequential vs Concomitant - OS &!! HR=0.84 [0.74;0.95], p=0.004 Survival (%) %! $! #! "!! '!)' '()$ &%)& "')% &!)$! & " ' #! ( Time from Randomization (Years) Absolute benefit in OS with concomitant CT: At 2 years: 5.3% At 3 years: 5.7% At 5 years: 4.5% &()& RT + conc CT RT + seq CT Auperin JCO 2010
21 V20 definition Percentage volume of the whole lung irradiated by more than 20 Gy Strong relationship between Grade II pneumonitis and V20 (p=0.005) V20 > 35% was associated with > Grade III esophagitis (p=0.032)
22 Other Approaches To Improve ChemoRadiotherapy Chemo Combinations
23 Other Approaches To Improve ChemoRadiotherapy Chemo Combinations Comparison of concurrent use of carboplatin-paclitaxel versus cisplatin etoposide with thoracic radiation for stage III NSCLC patients: A systematic review. C.E. Steuer ASCO 2015
24 Other Approaches To Improve ChemoRadiotherapy Chemo Combinations PROCLAIM! Stage III unresectable LA NSCLC! 1:1 rand. Stratify by:! PS 0 vs 1! gender! IIIA vs IIIB! PET scan use N=600 R 3 cycles of pemetrexed + cisplatin + radiation therapy (66 Gy in 33) sequenced to 4 cycles of pemetrexed Primary objective : survival Superiority design 80% Powered to detect Hazard Ratio= cycles of etoposide + cisplatin + radiation therapy (66 Gy in 33) sequenced to 2 cycles of platinum doublet consolidation Suresh Senan ASCO 2015
25 PROCLAIM Suresh Senan ASCO 2015
26 Other Approaches To Improve ChemoRadiotherapy Chemo Combinations A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.
27 Other Approaches To Improve ChemoRadiotherapy Chemo Induction Ph III CALGB Objetive: increased 40% median survival from 13 m to 18.2 m Vokes JCO 2007
28 Induction Chemo: Ph III CALGB MST (mos) 2-y OS (%) 3-y OS (%) CT/RT IND Vokes JCO 2007
29 Other Approaches To Improve ChemoRadiotherapy Chemo Consolidation The Hoosier Oncology Group and US Oncology ChemoRT Cisplatin 50 mg/m 2 IV d 1,8,29,36 Etoposide 50 mg/m 2 IV d 1-5 & Concurrent RT 59.4 Gy (1.8 Gy/fr) Stratification Variables: PS 0-1 vs 2 IIIA vs IIIB CR vs. non-cr Randomize Primary objective: Overall survival Secondary objectives: PFS, toxicity Aim: to detect improvement in overall survival of 25 mos vs. 19 mos Docetaxel 75 mg/m 2 q 3 wk! 3 Observation Hanna JCO 2008
30 The Hoosier Oncology Group and US Oncology Percent of Patients Surviving 100% 75% 50% 25% 0% All Patients: Median: 21.7 months 3 year survival rate 30.2% Observation: Median: 23.2 months 3 year survival rate: 26.1%. Docetaxel: Median: 21.2 months 3 year survival rate: 27.1% P-value: Months since Registration Randomized Patients (n=147) All Patients (n=203) All Patients Observation (Randomized pts) Docetaxel consolidation (Randomized pts) Hanna JCO 2008
31 Other Approaches To Improve ChemoRadiotherapy Chemo Consolidation Study MST (months) 2 year 3 year 4 year 5 year S9504 (PE/RT! D) Clin Lung Cancer (18-35)* 54% (43-65)* 37% (24-55)* 29% (19-29)* 29% (19-29)* S9019 (PE/RT! PE J Clin Oncol (10-22)* 34% (21-47)* 17% (7-27)* 17% (6-28)* 17% (6-28)* *95% CI PE: Cisplatin/Etoposide; RT: Radiotherapy (61 Gy); D: Docetaxel Gandara, et al. J Clin Oncol 2003;21: Gandara, et al. Clin Lung Cancer 2006;8:
32 Other Approaches To Improve ChemoRadiotherapy Chemo Consolidation and Maintenance Kelly JCO 2008
33 Other Approaches To Improve ChemoRadiotherapy Chemo and Maintenance Butts Lancet Oncol
34 Other Approaches To Improve ChemoRadiotherapy Others Clinical Trials
35 PACIFIC Day 1 Max 42 days after the end of chemoradiation Re-treatment for patients who have experienced disease control at end of 12 months treatment but progressed during follow-up Patients with unresectable NSCLC ( Stage III) who have not progressed following definitive, platinum-based, concurrent chemoradiation N = 702 2: 1 Arm 1 MEDI mg/kg Q2W for up to 12 months (MAX 26 doses) Arm 2 Placebo (matching placebo for infusion Q2W iv for up to 12 months (MAX 26 doses) OS PFS using PI assessments according to RECIST 1.1* Follow-up Period MEDI4736 will commence treatment on Day 1 and continue on a Q2W schedule for a maximum of 12 months (26 doses) or until PD IV administration
36
37 Other Approaches To Improve ChemoRadiotherapy XRT Dose A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.
38
39 Other Approaches To Improve ChemoRadiotherapy XRT Dose
40 Recommendations ASCO Unresectable stage III NSCLC. A. In unresectable stage III disease, chemotherapy plus radiotherapy prolongs survival compared with radiation alone and is most appropriate for individuals with good performance status ESMO The preferred treatment of unresectable LA-NSCLC is definitive concurrent chemotherapy and radiotherapy with a dose no less than the biological equivalent of 60 Gy in 2.0 Gy fractions [I, A]. Vansteenkiste Ann Onco 20133; Pfister JCO 2004
41 Conclusions Over the past 50 years combined modality regimens for inoperable stage III NSCLC have almost tripled the median survival of this disease
42 Conclusions Multi modality treatment play a key role in stage III Treatments should be evaluated by a multidisciplinary team Concurrent chemoradiotherapy is the standard of care for fit patients with unresectable stage III NSCLC Any third generation chemotherapy can be given at full dose when combined with thoracic radiation
43 GRACIAS
Combined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
Heterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
Lung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
Tratamiento Multidisciplinar del CNMP Localmente Avanzado. Luis Paz-Ares
Tratamiento Multidisciplinar del CNMP Localmente Avanzado Luis Paz-Ares Indice Definición & Estadios Estadio IIIA N2 Estadio IIIB (y N2 irresecables) Conclusiones Indice Definición & Estadios Estadio IIIA
Disclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
Stage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
Debate on stage III NSCLC: The role of systemic therapy
1 Debate on stage III NSCLC: The role of systemic therapy Rolf Stahel University Hospital of Zürich Bucharest, 16.6..2015 2 Stage III disease: The problem of heterogeneity, the risk of distant metastases
Is the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
Casi clinici di integrazione multiprofessionale: NSCLC stadio III. Biagio Ricciuti. Scuola di Specializzazione in Oncologia Medica
Casi clinici di integrazione multiprofessionale: NSCLC stadio III Scuola di Specializzazione in Oncologia Medica Università degli Studi di Perugia Outline Standard treatment Open questions Clinical cases
Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC
Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC George R. Blumenschein, Jr., MD Associate Professor of Medicine Department of Thoracic/Head & Neck Medical Oncology The University
Practice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
Adjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia
Adjuvant Therapy in NSCLC Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Agenda What do we expect today from new adjuvant chemotherapy Which data do we have with targeted agents
Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
Lung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
Chemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
Multidisciplinary interactive session (MIS) pn2: The optimal treatment in Wilfried Ernst Erich Eberhardt
Multidisciplinary interactive session (MIS) pn2: The optimal treatment in 2012 Wilfried Ernst Erich Eberhardt Department of Medicine (Cancer Res.), University Hospital Essen, West German Cancer Centre,
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
Adjuvant radiotherapy for completely resected early stage NSCLC
Adjuvant radiotherapy for completely resected early stage NSCLC ESMO Preceptorship on lung Cancer Manchester March 2018 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique
RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?
ESMO Preceptorship Programme NSCLC Singapore 13 14 dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA
Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
Combining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
What is Next for Patients with Stage III Non-Small Cell Lung Cancer?
What is Next for Patients with Stage III Non-Small Cell Lung Cancer? Walter J Curran, Jr, MD Executive Director Winship Cancer Institute of Emory University Atlanta, GA NRG Oncology Group Chairman 1 Stage
Systemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
Neo-adjuvant chemotherapy in NSCLC
SCLC Epidemiology eo-adjuvant chemotherapy in SCLC Sarita Dubey sst Professor, Medical ncology, UCSF UCSF/UC Davis Thoracic conference ovember 8, 2008 Statistics for 2008 Cancer Incidence Deaths Colon
Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
The population of patients with stage III non
GREGORY M.M. VIDETIC, MD, CM, FRCPC Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH Locally advanced non small cell lung cancer: What is the optimal concurrent
Adjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
The 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
11/21/2009. Early Stage. Stage III. From Mountain: Chest, 1997
Combined odality egimens in Locally dvanced SCLC: Current Status and Future irections Primo. Lara, Jr, Professor of edicine University of California avis Cancer Center arly Stage Stage Five-Year Survival
Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
Concurrent and sequential chemoradiotherapy. P. Van Houtte Department of Radiation Oncology Institut Jules Bordet
Concurrent and sequential chemoradiotherapy and radiotherapy for NSCLC P. Van Houtte Department of Radiation Oncology Institut Jules Bordet RADIOTHERAPY & CHEMOTHERAPY A very old concept «Benzene could
Locally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
Professor and Head Division of Radiation Oncology Stellenbosch University and Tygerberg Hospital Cape Town South Africa
STAGE III NONSMALL CELL LUNG CANCER TREATMENT APPROACHES WE LIKE TO PRACTICE... ALMOST UNETHICALLY Branislav Jeremic, MD, PhD Professor and Head Division of Radiation Oncology Stellenbosch University and
Stato dell arte del. Antonio ROSSI, MD. Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY
Stato dell arte del trattamento del microcitoma Antonio ROSSI, MD Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY Truly has become small. Last session/day in all meetings One chemo
Treatment of LS (Stage I-III) SCLC
Treatment of LS (Stage I-III) SCLC Prof C Faivre-Finn Manchester Lung Cancer Group Manchester Radiation Related Research Group ESMO-The Christie Preceptorship programme on Lung Cancer 9 th March 2018 @finn_corinne
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer?
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer? ~A pooled analysis of the literature~ Satomi Yamamoto 1, Kazuyuki
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
SCLC: Developments in systemic treatment
SCLC: Developments in systemic treatment Egbert F. Smit, Dept. Pulmonary Diseases, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands Staging Outline First line treatment Second line treatment
Combined modality treatment for NSCLC with N2 disease
Combined modality treatment for NSCLC with N2 disease Gerry Hanna Senior Lecturer and Consultant in Clinical Oncology Centre for Cancer Research and Cell Biology @gerryhanna E: g.hanna@qub.ac.uk Talk Outline
Mediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
The surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
Cooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
Adjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
Allan Price NHS Lothian, Edinburgh, UK
Allan Price NHS Lothian, Edinburgh, UK Radiotherapy Dose Volume Timing Technique PCI Surgery Systemic agents 1 Study Dose Time Induction CT Ann Arbor 65.1-75.6 Gy Duke 73.6-80 Gy RTOG 77.4 Gy 74 Gy 6.5-7.5
Treatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
Editorial Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer Pascale Tomasini 1,2, Laurent Greillier 1,2, Arnaud Boyer 1,2, Arnaud Jeanson 1,2, Fabrice Barlesi 1,2 1 Aix Marseille
17th ESO ESMO Masterclass in Clinical Oncology
NSCLC Radiotherapy Prof Corinne Faivre-Finn Manchester Radiotherapy Related Research Group Manchester Lung Cancer Group The Christie, Manchester, UK 17 th ESO-ESMO Masterclass 25 th March 2018 Early stage
The Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy fortune favours the bold
Editorial Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy fortune favours the bold Surein Arulananda 1,2,3, Paul Mitchell 1,3,4 1 Cancer Immuno-Biology Laboratory,
Are we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
Optimal Treatment of Unresectable Locally Advanced NSCLC. Sponsored by a Grant from the Bonnie J. Addario Lung Cancer Foundation
Optimal Treatment of Unresectable Locally dvanced SCLC Howard (Jack) West, M Medical Oncologist Medical irector, Thoracic Oncology Program Swedish Cancer Institute Seattle, W February, 2009 President &
The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
Slide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
Treatment of Stage I-III SCLC
Treatment of Stage I-III SCLC Prof C Faivre-Finn Manchester Lung Cancer Group Manchester Radiation Related Research Group ESMO-The Christie Preceptorship programme on Lung Cancer 3 rd March 2017 @finn_corinne
Lung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
Radiotherapy in NSCLC: What are the ESMO Guidelines?
- The role of radiation in early stage - RT/CT for unresectable NSCLC - Brain metastasis - Oligometastatic disease Radiotherapy in NSCLC: What are the ESMO Guidelines? Jean-Yves DOUILLARD MD PhD Chief
Thoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
Place de la radiothérapie dans les CBPC métastatiques
Place de la radiothérapie dans les CBPC métastatiques Cecile Le Péchoux, 12 ème Biennale Monégasque de Cancérologie, 2016 IOT Institut d Oncologie Thoracique CBPC metastatique Rapid doubling time, early
Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
LUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
NRG Oncology Lung Cancer Portfolio 2016
NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
Cancer Biology 2016;6(1)
Weekly Docetaxel and Cisplatin with Concomitant Radiotherapy in Addition to Consolidation Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer Hanan G. Mostafa and Mohamed-Alaaeldeen H. Mohamed
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
LUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
EGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
The role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
CANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
Stage III Non Small Cell Lung Cancer Concurrent Treatments and Toxicities
Stage III Non Small Cell Lung Cancer Concurrent Treatments and Toxicities Dr. Khalid Hirmiz MD,FRCPC Radiation Oncologist Cancer Education Day Friday, April 13,2018 No Disclosures Objectives Review the
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
Ruolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)
Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,
THORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer. Dr P Vijay Anand Reddy Director Apollo Cancer Hospital
Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer Dr P Vijay Anand Reddy Director Apollo Cancer Hospital H&N Ca - Disease Burden 15-20% of all cancers in India, 8% worldwide